康方(09926.HK)續漲11%再創紀錄高 公布自主研發胃癌藥及與中生研發肝癌藥具良好安全耐受
康方生物-B(09926.HK)公布與中生製藥(01177.HK)共同研發治療晚期肝癌及核心自主研發治療晚期胃癌藥的最新研發結果顯示出良好安全耐受性。康方承昨天股價考驗10天線獲支持倒升勢,今天再創紀錄高,最高見56.7元,現造55元,續漲11%,成交619萬股,涉資3.38億元;中生繼昨天股價扭六連跌重越10天線後,今早進一步升破50天及20天線,最高見7.78元,現造7.68元,續升4.2%,成交7,663萬股,涉資5.87億元。
康方生物公布,與中生製藥共同研發的抗PD-1單抗藥物派安普利(安尼可)聯合安羅替尼一線治療晚期肝癌(HCC)的最新研究在2021年國際胃腸道癌症研討會上發佈。研究認為,派安普利聯合安羅替尼組合安全耐受,作為晚期HCC患者的一線治療表現出令人鼓舞的抗腫瘤活性。
此外,康方核心自主研發兼全球首創的新型腫瘤免疫治療雙特異性抗體新藥Cadonilimab聯合化療一線治療晚期胃癌或胃食管結合部腺癌的Ib/II期臨床研究最新結果在2021年國際胃腸道癌症研討會上發佈。研究顯示,Cadonilimab10毫克/千克每兩星期一次(Q2W)聯合化療一線治療GC或GEJ顯示出良好的安全性和耐受性。與化療聯合一線治療GC或GEJ,Cadonilimab在各劑量水平下均表現出令人鼓舞的抗腫瘤活性、持續的腫瘤應答,並可改善晚期GC患者的無進展生存期。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.